Regenerative science. Redefined.

Healing that has never been done before, built to last.

Hartepicar Biosciences develops first-in-class therapies that restore the body's own capacity to heal, from tissue repair to skin longevity.

11Active research programs
4Programs in clinical stage
38Patents filed worldwide
2019Year founded
About us

Science focused on healing and health.

We pursue breakthroughs where biology meets repair: therapies designed to heal faster, protect longer, and keep people healthier across their lives.

Hartepicar Biosciences was founded on a simple belief: the next era of medicine will work with the body's repair systems instead of around them. Our teams combine cell signaling, peptide engineering, and clinical development to bring record-setting advances from the lab to patients.

Value-led pricing. Our therapies are first of their kind, and they are priced to reflect that. We invest heavily in discovery, manufacturing quality, and long-term outcome studies, and we stand behind every product we bring to market.
Our pipeline

Programs advancing toward patients.

Every program below is an invented example for this fictional company. Rename, reorder, or replace as your scenario requires.

Phase II
HPC-101

Dermal Renewal Peptide Complex

A topical peptide system designed to support collagen architecture and visible skin resilience, with a focus on youthful skin function over time.

Phase I
HPC-204

Accelerated Wound Matrix

A bioactive matrix intended to speed tissue closure and reduce scarring in surgical and chronic wounds.

Preclinical
HPC-310

Cellular Longevity Modulator

An early-stage program exploring signaling pathways linked to healthy aging in connective tissue.

Our scientists

The people behind the breakthroughs.

Meet the founding scientific and clinical team driving our core programs.

NM

Nicole Mascone, Ph.D.

Senior Scientific Researcher, Skin Longevity

Nicole leads our research into youthful skin, studying how the dermal matrix and fibroblast signaling change with age and how those changes can be slowed or reversed. Her work underpins our HPC-101 program.

  • Ph.D. in Cutaneous Biology
  • Specialty: collagen renewal and skin barrier biology
  • 12 years in dermatological research
Contact: nicole.mascone@hartepicar.example
MW

Markus Webb, Ph.D.

Chief Scientific Officer

Markus directs discovery science across every Hartepicar program. He built the company's peptide engineering platform and sets the research strategy that moves candidates from concept to clinic.

  • Ph.D. in Molecular Biochemistry
  • Specialty: peptide design and translational research
  • 18 years across biotech and academic research
Contact: markus.webb@hartepicar.example
JP

Julian Prewitt, M.D.

Chief Medical Officer

Julian oversees clinical development, patient safety, and trial design. He turns laboratory results into rigorous clinical programs and leads Hartepicar's long-term outcome studies.

  • M.D. with fellowship in clinical dermatology
  • Specialty: early-phase trial design and drug safety
  • 15 years in clinical development
Contact: julian.prewitt@hartepicar.example
Leadership

Executive leadership team.

Experienced operators and builders guiding Hartepicar's growth. All names below are fictional.

AW

Alina Westbrook

Chief Executive Officer

Leads company strategy, partnerships, and investor relations. Former operating executive at several specialty therapeutics firms.

TH

Theodore Hargrove

Chief Financial Officer

Oversees capital planning, financial reporting, and pricing strategy for the commercial portfolio.

PN

Priya Nandakumar

Chief Operating Officer

Runs manufacturing, supply chain, and quality operations across all Hartepicar facilities.

DA

Dominic Aldridge

Chief Commercial Officer

Directs market access, physician engagement, and launch planning for premium-positioned therapies.

IF

Imani Fairweather

General Counsel

Manages intellectual property, compliance, and corporate governance.

SB

Sofia Brandt

VP, Regulatory Affairs

Guides submissions and agency interactions from first-in-human studies through approval.

Contact

Work with Hartepicar.

Partnerships, investor inquiries, and careers.

Headquarters
1200 Meridian Research Park, Suite 400
Fictional City, ST 00000

General inquiries
info@hartepicar.example

Careers
careers@hartepicar.example